Healthcare Professional and Patient Surveys to Evaluate the Effectiveness of the Risk Minimisation Educational Materials for Certolizumab Pegol (CZP; CIMZIA®)

Study identification

• EU PAS number:
  EUPAS14867
• Study ID:
  32795
• Official title and acronym:
  Healthcare Professional and Patient Surveys to Evaluate the Effectiveness of the Risk Minimisation Educational Materials for Certolizumab Pegol (CZP; CIMZIA®)
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  France

  Germany

  Greece

  Norway

  Sweden

  United Kingdom
• Study description:
  The purpose of this Post-authorisation safety study (PASS) is to evaluate the effectiveness of the education material risk minimisation measures being implemented in the EU, in healthcare professionals prescribing CZP and patients who are prescribed CZP
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:19/07/2016

Actual:19/07/2016

Study start date

Planned:01/08/2016

Actual:01/08/2016

Data analysis start date

Planned:31/07/2019

Date of final study report

Planned:30/11/2019

Actual:30/11/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

UCB Biopharma SPRL

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)